WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Targeted Drug Delivery Systems (TDDS): Literature Review

Ajay Kumar Singh

(Mur2100755), Bachelor of Pharmacy, Mewar University, Gangrar, Chittorgarh, Rajasthan
Email: ajaysingh0906578@gmail.com

ABSTRACT

Targeted Drug Delivery Systems (TDDS) have become a revolutionizing development in pharmaceutical science and are used as an effective method allowing the targeting of specific diseased cells or tissues with the intention of reducing systemic side effects. This review of the literature in peer-reviewed published articles shows the increasing trend in the use of nanotechnology, ligand-based targeting and stimuli-responsive carriers to improve therapeutic properties. The method employed, therefore, entails a synthesis of the literature to describe the efficacy, difficulties, and practice applicability of TDDS. The present investigation suggests that among the nanocarriers, liposomes, micelles, and polymeric nanoparticles have a great prospect for managing cancer and chronic disease. Still, some problems deserve to be considered as serious, for example, biological variability, limited drug loading capacity, scalability problems, and regulation issues. A few of the ethical issues discussed include patient safety, issues of openness in sharing data as well as fairness in the distribution of such therapies. However, the future of TDDS seems quite bright, with advancements being made towards artificial intelligence for operation, biodegradable materials for scaffolds and new drug delivery strategies based on installed in the human body. TDDS has a great perspective of becoming one of the key approaches in contemporary medicine that can enhance drug specificity, decrease its side effects, and increase patients' compliance. Furthermore, interdisciplinary investigation and careful clinic implementation are necessary for the future development of its use.

Keywords: *Targeted Drug Delivery, Nanotechnology, Nanocarriers, Controlled Drug Release, Precision Medicine, Stimuli-responsive Systems, Ligand-based Targeting, Personalized Therapy, Biocompatible Materials, Cancer Therapy.*

Introduction

A targeted drug delivery system (TDDS) can be considered an innovation around pharmacology since pharmaceutical drugs have many disadvantages when they are administered through regular methods. Current methods have unrestricted access of drugs to other tissues and organs in the body thus limiting the concentration at the required site and hence causing minimal efficacy and side effects. On the other hand, TDDS will ensure that the therapeutic agents are targeted on the cells, tissues, or organs that are affected and not on the healthy ones, as it just delivers higher concentrations of the drug to the affected area.

The underlying principle of TDDS is to increase the bioavailability of existing drugs, decrease the toxicity and deliver the drug in a controlled or sustained manner. They utilize modern carriers like nanoparticles, liposomes, micelles, and ADCs to deliver the drugs to specific sites required. TDDS is especially useful in diseases involving the treatment of organs, such as tumours, cancer, cardiovascular diseases, and neurological disorders, among others, where precise delivery of drugs to the target region is important.

Personalized therapy and precision drugs have lately taken centre stage in discussions about cancer therapy and many other diseases, and therefore, advances in targeted drug delivery are considered an interprofessional science that combines pharmaceutical science, molecular biology, material science, and nanotechnology. This paper seeks to analyze existing TDDS as well as new developments in the field, its limitations and its prospects in the constantly evolving drug delivery systems today.

Background

Thus, the novel concept of Targeted Drug Delivery Systems (TDDS) has come up to address the complexity and uniqueness of current treatments. As for conventional drug delivery, the agents are delivered through the systemic circulation and thus expose all the tissues/ organs of the body. This is a non-site-specific deposition, and it contributes to a low drug concentration at the desired site and a high concentration in the normal tissues, resulting in side effects. However, such methods are somewhat limited, and that has led to the development of more complex methodologies, one of which is TDDS. TDDS are designed to deliver therapeutic agents to the target of pathological tissues/ organs but not causative ones. TDDS can be defined as the use of disease-related biological information, including the EPR effect, receptor-mediated targeting of tumours or target diseases to transport drugs to the target

sites. This approach enhances not only the potency of the drug but also the amount needed for the drug dose and the systemic toxicity, a factor of great importance in chemotherapy, where issues to do with cytotoxicity are of major importance [1] [2].

This history of TDDS is traced back to the earlier 1970s with the formation of the initial liposomal drug carriers. Since then, remarkable advances have been in carriers' design and delivery systems. In the current world, several carriers, including nanoparticles, liposomes, microspheres, dendrimers and polymeric micelles, exist and are used in the delivery of drugs in a controlled and directed manner. These carriers can function with ligands, antibodies or peptides that have affinity for the markers on the target cells so as to achieve active targeting. It is seen that TDDS has found significant uses in oncology manufacturing through methods such as antibody-drug conjugates (ADCs), which work and function in the same manner as monoclonal antibodies and potent chemotherapeutic agents. Others are cardiovascular therapy, Neurology and Infectious diseases since localized delivery can be helpful in improving the results of the treatment [3] [4].

Furthermore, in recent years, nanotechnology, as well as the science and engineering of biomaterials, has provided the concept of a smart drug delivery system where the release of the drug is influenced by stimuli such as pH, temperature or enzymes at the site of action. They contributed to an independent and specific diagnosis of diseases as well as brought more efficient treatment, which differs in the case of different patients. Overall, TDDS are a new generation in drug therapy that focuses on enhancing intracellular target selectivity, the reduction of side effects, and overall improvement of the treatment results. They still hold promises that can transform the face of the healthcare system in the near future [5] [6].

Literature Review

The Need for Targeted Drug Delivery Systems

This paper aims to offer a good background of targeted drug delivery by explaining its reasons. It defines the problems of the standard systems, which include, for instance, systemic toxicity, low bioavailability and non-compliance of the patient. The authors point out that more elaborate methods are needed due to the late cancer, which presents itself in heterogeneity and pathological microenvironments. Some of them are passive, and others are active, where the passive targeting is based on the EPR effect while the active targeting depends on ligand-receptor interaction. The study also points out how TDDS can penetrate biological barriers and enhance the journey of the pharmacokinetics/pharmacodynamics of drugs. More importantly, the article creates an impression of why TDDS are important in today's therapeutic disciplines. Thus, referring to the difference between traditional and targeted drug delivery approaches, the latter answers the need for the drug to act only at a certain site and to have a controlled release. The authors suggest the cooperation of various departments in order to overcome those technical difficulties connected with the realization of TDDS. In general, this work serves as one of the basis for envisioning future drugs [7].

Advantages and Types of Targeted Drug Delivery Systems

The benefits of using TDDS are the following: It states that some of the advantages of TDDS are increased solubility of the drug, longer duration of circulation, less frequency of dosing and lowered systemic toxicity. These are passive targeting, which is based on the physiological properties of the drug; active targeting, which is dependent on the interactions between ligands and receptors, and physical targeting, which intends to be triggered by certain conditions such as heat or ultrasounds. Liposomes, nanoparticles, dendrimers and antibody drug conjugates are perceived as common delivery systems in this case. The article also discusses the practical uses of TDDS in cancer, HIV, cardiovascular and ocular disease treatment. Another important aspect would be the potential benefits of TDDS in terms of controlling and prolonging drug release rates to have better therapeutic coefficients and patient compliance. Also, the article addresses certain issues, such as complications in two-shot forming, higher cost, and dimensional instabilities. Nevertheless, it notes that in long-term or potent treatment diseases clinical advantages overshadow the shortcomings. As it will be seen, this source also has the value of offering a general and popular explanation about the topic of TDDS that supplements academic approaches [8].

Chitosan Nanoparticles as Carriers

In the study of this work, chitosan-based nanoparticles will be evaluated for possible use in TDDS. Chitosan is a biopolymer that has biomedical applications due to factors such as its biodegradability, and biocompatibility. The authors give a procedure of preparation and loading carvacrol into chitosan nanoparticles via ionic gelation. The drug release study in vitro revealed prolonged and steady release and it was seen that there is no initial sudden burst effect. This research also explains the process of active targeting through the functionalization of chitosan nanoparticles with targeting ligands. Also, chitosan exhibits a positive surface charge that increases interaction and the compound with negatively charged cellular membranes, thus increasing internalization. Therefore, the authors suggest that chitosan-based carriers are applicable to oral, nasal, and ocular systems of drug delivery. Some of the drawbacks are that they are not suitable for use in an unstable, acidic environment and may also be difficult to produce on a large scale. Consequently, this paper is in favour of utilizing degradable, biodegradable polymers such as chitosan in TDDS and offers information on the performance characteristics of such systems [9].

Antibody-Drug Conjugates (ADCs)

In this article about ADCs, the details of this approach are described as a complex version of TDDS. This involves attaching a monoclonal antibody with a cytotoxic agent through a chemical linker that should not break easily. The antibody targets antigens present in tumour cells in order to deliver the toxic effects of the drug directly. They reduce harm to clinically healthy tissues and improve the accuracy of the delivery of the treatment. One instance that the article considers is Trastuzumab emtansine (T-DM1), which is used for HER2-positive breast cancer for which clinical trials are successful. The major limitations that are related to this strategy are immunogenicity, the stability of the linker and the possibility of side effects. However, due to steady

development of knowledge and improvements, ADCs are gradually evolving as more selective and safer. It also went further to discuss the current pipeline of ADCs already in development for hematologic and solid cancers. This brings out the fact that ADCs reflect the future of cancer treatment, with better therapeutic outcomes and fewer adverse effects associated with chemotherapy [10].

Polymer-Based Smart Pills

This article focuses on a polymer pill that can stay in the stomach for several weeks to give a slow and continued release of the medication. The pill known as LYO-PPL was formulated by Lyndra Therapeutics and, when taken, deforms into a star shape that cannot be broken down in the stomach while releasing drugs in a controlled manner. This is because the product's core innovation is allowing for equal drug concentration to be administered every day and night with the pill, which is especially helpful for chronic illnesses such as schizophrenia and malaria. As mentioned in the article, the current technology comprises a combination of pharmaceutical science and mechanical engineering to design advanced TDDS. Finally, it reflects on issues of taking medication in developing countries, extended-stroke dosage form and its social implications. Some of the concerns associated with it are safety, biocompatibility, and ease of elimination if complications arise. This review describes how it is possible to enhance physical design to control drug delivery kinetics thus minimizing the conventional chemical targeting methods. It is germane to highlight that the idea of creating smart pills is an innovation that helps to avail long-term treatment [11].

Stimuli-Responsive Nanoparticles in Targeted Therapy

This review mainly focuses on the synthesis and use of stimuli-responsive nanoparticles (SRNPs) in drug delivery. SRNPs with addresses are edged to release medicine at targeted sites as a result of specific stimuli like pH, temperature and enzyme activity; this is valuable in that it cuts down the side effects of the drug by delivering high concentration at the targeted site. In this paper, the authors explain several types of SRNPs: pH-sensitive, thermo-responsive, and enzyme-sensitive, as well as applications of these types for chronic diseases, such as cancer, diabetes and cardiovascular diseases. Based on the review, the definitions of SRNPs would be that they are flexible, patient-centred, and aimed to meet the needs of patients with multiple chronic diseases with diverse disease-specific microenvironments. It also talks about the current issues, including stability and preciseness and calls for more clinical studies to prove the efficiency of these nanocarriers. Based on these findings, the authors state that although the SRNPs have great potential to change the current targeted therapy paradigm, more collaborative studies are needed to address challenges and assumptions associated with the approach in order to bring the concept into clinical practice [12].

Nanofiber-Based Systems for Dual Drug Delivery

These classifications include the overall background and development of nanofiber drug delivery systems, with a special emphasis on drug delivery systems that release two or more drugs and can be released in response to stimuli. Nanofibers possess a significantly high surface area to volume ratio and controllable pore structure, thus requiring several drugs to be loaded on them. Several fabrication techniques used are explained by the authors as well as an overview of how these methods affect the physicochemical characteristics of nanofibers. Special focus is paid to the design of nanofibers that are capable of releasing the drug upon exposure to a particular stimulus like change in pH level, temperature or the action of specific enzymes. The review also discusses the concept of using drugs with combined action that has the potential of increasing effectiveness in various diseases such as cancer. There are certain issues that additional frameworks have to overcome, some of which are scalability, reproducibility and biocompatibility. The authors believe that the nanofiber systems should be integrated with other delivery systems so as to form a drug delivery system with a range of functions. They concluded that although the current nanofiber-based system offers a promising future, eradicating prevailing challenges is essential for translating nanofiber into the clinic [13].

Stimuli-Responsive Nanogels in Cancer Therapy

In this review, stimuli-responsive nanogels are described and discussed as intelligent drug delivery systems with an emphasis on cancer treatment. Nanogels are three-dimensional crosslinked hydrogel systems with the ability to capture drug molecules and are capable of delivering drugs or releasing them in light of stimuli like pH, temperature or redox environment. In this work, the authors describe possible methods of nanogel synthesis and how the latter's properties can be adjusted to create the desired responsiveness. These benefits of nano gels include having a greater drug-carrying capacity, non-toxicity, and potential for controlled and party-specific release of drugs. Some examples of how stimuli-responsive nanogels can be applied to deliver chemotherapy drugs to the tumour site are provided. Some of the problems which are associated with this new compound may include toxicity, stability problems and the fact that the compounds must be synthesized on a rather large scale. In light of this, the authors reiterate that stimuli-responsive nanogels present a rational strategy for cancer therapy, though further study is required to establish the angel's bioarcheological behaviour and effectiveness in treating cancers without any health complications [14].

Stimuli-Responsive Hydrogels as Smart Drug Carriers

This review article delves into the recent progress in the development of stimuli-responsive hydrogels for smart drug delivery applications. Hydrogels can be developed to be responsive to some factors including pH, temperature, light or particular biomolecules and thus be used for controlled drug delivery. The authors elaborate on these hydrogels and their network structures and functional groups and how these elements can be tuned to make them responsive. Examples in cancer carcinoma, diabetes mellitus, and individual and inflammatory diseases are all demonstrated to elaborate the utility of these systems. The review also presents some concerns, such as the synthesis issue, the immune reaction, and the adjustment of the release rate. In prospect, it is proposed to develop multifaceted responsive hydrogels when several of the designed elements would be incorporated into the hydrogel to enable the hydrogel to respond to diverse pathological conditions. The authors suggest that stimuli-responsive hydrogels have the potential to be smart

carriers and serve as novel strategies for delivering drugs, but more studies are required in the future to address the existing problems before the potential application of these carriers in clinics [15].

Ligand-Targeted Nanocarriers for Precision Drug Delivery

This paper provides comprehensive information on ligand-targeted nanocarriers in TDDS, especially in the application of cancer therapy. The authors also look into the methods of active targeting ligands encompassing liposomes, micelles, and dendrimers. Through modifying a ligand that is overexpressed on tumour surfaces or cell surface receptors such as folate receptors or transferrin receptors, ligand-conjugated systems allow the targeted delivery of chemotherapeutic agents, thus minimizing the uptake of healthy tissues.

The review also explains the factors that lead to a high specificity of the frontal ligands, such as choosing the ligand, its density, and its position on the carrier's surface. The following are the enlisted preclinical and clinical accomplishments and a few ligand-conjugated formulations under trial. However, the authors also resonate on issues like the variation in receptor expression, endosome problems, and off-target effects. Notably, targeting ligands must be used in conjunction with stimulus-responsive strategies to develop the generation of potent multi-functional carriers. In their review, the authors acknowledge the importance of ligand-targeted nanocarriers in the development of personalized oncology. However, the authors emphasize the need for enhancement of their design, assessment, and testing. This article could be useful to the understanding of the combining of molecular recognition with nanotechnology for the modern TDDS [16].

Methodology

This paper uses a qualitative approach and relies on other published research to assess the progress, issues and future of the Targeted Drug Delivery Systems (TDDS). The information wishes to harness advances made in the last decade on nanotechnology and advancements in pharmaceuticals as well as the approach is focused on a systematic consideration of articles published in peer-reviewed journals from the year 2020 to 2025. This sort of selection is helpful to undertake the analysis of the most recent and pertinent advancements in the proposed field.

1. Literature Search Strategy

The main sources of primary data were science peer-reviewed papers available in databases of PubMed, Science Direct, Springer Link, Wiley online library and Scopus. Some of the keywords used while searching for information include:

- ✓ "Targeted drug delivery systems"
- ✓ "nanoparticles in drug delivery,"
- ✓ "ligand-modified nanocarriers,"
- ✓ "stimuli-responsive drug delivery," and
- ✓ "controlled drug release mechanisms."

2. Inclusion and Exclusion Criteria

Articles were included if they:

- ✓ All of them were published between 2020 and March 2025.
- ✓ Focused on innovative TDDS technologies.
- ✓ The review section is comprised of quantitative research studies or qualitative synthesis, clinical or preclinical trials.
- ✓ Included possible uses in prevention or cure of diseases or formulation of or in drugs.

Exclusion criteria involved:

- ✓ Literature review-related publications, including prior and parallel research, that do not include TDDS.
- ✓ Non-peer-reviewed sources such as blogs or editorials.
- ✓ The articles had inadequate methodological or technical content and thus should be regarded as lacking these aspects.

3. Data Extraction and Synthesis

In this case, the literature that was selected was critically reviewed in order to determine the findings as regards:

- ✓ Drug delivery mechanisms (e.g., passive vs. active targeting).
- ✓ Types of nanocarriers (liposomes, dendrimers, micelles, etc.).
- ✓ Stimuli-responsive release strategies (pH, temperature, enzymes).
- ✓ Therapeutic applications (especially in cancer, neurological disorders, and infections).

4. Ethical Considerations

This research review uses existing academic publications since it does not ask for direct subject or material participation. Since this review article engages only with published materials, it does not need official approval. Professional and academic standards govern the maintenance of ethical integrity throughout the entire research period. Every piece of literature in this report originated from peer-reviewed scientific journals which ensures both reliability and accuracy as well as credibility. The sources were presented with absolute objectivity while avoiding any form of incorrect interpretation or manipulated data. The study exists without any commercial influence or conflict between researchers. The choice of material stemmed exclusively from source alignment to the research topic and scientific validity and knowledge advancement in drug delivery platforms. The source material has not undergone any changes because researchers present unmodified original information throughout the study.

This report follows ethical research practices to preserve academic integrity while making responsible contributions to pharmaceutical sciences and biomedical engineering body of knowledge.

Analysis

This collected literature study shows more advancement in Targeted Drug Delivery Systems (TDDS) in terms of nanotechnology, biomolecular targeting and stimuli-sensitive release systems. Based on the journals that were reviewed, there is a clear transition from systemic-based therapy to precision-based therapy, whose major goal is to increase the chance of positive therapeutic outcomes while at the same time minimizing the side effects of systemic toxicity.

1. Advancements in Nanocarrier Design

One of the most important aspects observed in various studies is the use of versatile delivery systems like liposomal, dendrimer, micellar, and polymeric nanoparticles. These are designed to contain therapeutic agents and release them at the targeted sites of tissues or cells that are affected by diseases. Research shows that the use of ligands at the surface includes antibodies, aptamers, and peptides in active targeting, especially for cancer treatment. They not only enhance the solubility and bioavailability of BCS class II and IV drugs but also have controlled and sustained release profiles to optimize the therapeutic windows.

2. Targeting Strategies and Mechanisms

The literature indicates two key targeting strategies, out of which one is passive targeting while the other is active targeting. Passive targeting relies on the enhanced permeability and retention (EPR) effect, predominantly in tumour tissues. However, many recent philosophies suggest that EPR effect–based delivery on its own is inadequate mainly because tumour endothelial organization is highly diverse. More selective and efficient targeting can be accessed through active targeting, as it depends on the ligand-receptor binding; nonetheless, the process necessitates an accurate and optimal choice of ligands. The improvement of targeting outcomes Several studies have shown that the approach of constant passive and active targeting mechanisms offers the best outcomes.

3. Stimuli-Responsive Delivery Systems

Another advanced development is the stimulus-sensitive nanocarriers that deliver medications in accordance with the change of pH, temperature, enzyme, or redox state. These strategies are Cumulatively advantageous in the following ways: This smart release strategy is especially useful under conditions where the delivery system needs to cross intracellular compartments or tumour microenvironments. It has been found that pH-sensitive polymeric micelles demonstrated increased drug perforation in cancer cells in response to tumour microenvironment pH, thus increasing its killing effect on the cancer cells.

4. Therapeutic Applications and Efficacy

A large part of the examined works raises the perfect application of TDDS in oncology as an alternative to conventional chemotherapy treatments. New developments being investigated for present-day use include other areas such as neurodegenerative disorders like the crossing of the blood-brain barrier, infection diseases, and autoimmune diseases. When comparing the results with the targeted delivery system, it was found that the drug concentration was higher at the targeted site, less frequency of dose administration, and high patient concordance.

5. Limitations and Challenges

Nevertheless, certain disadvantages have kept the Targeted Drug Delivery Systems (TDDS) from being commercialized. One of the major issues is that the biological contexts of target diseases vary for example, cancer cells or receptors are heterogeneous – thus, active targeting approaches commonly incur significant inaccuracies. This can lead to the undesirable drug accumulation and therapeutic ineffectiveness of the drug being administered. Some principles need to be addressed; one of them is the stability of the nanocarrier. In many cases, carriers of DEBs degrade prematurely, or the drugs get released in a non-specific manner by the enzymatic action or through the blood, thus reducing the efficiency of the system. However, there are problems associated with drug loading and its ability to control the release rate, which can be severe as and when the drug being encapsulated is large or hydrophobic.

From the manufacturing process standpoint, two main challenges are faced in reproducibility in the nanocarrier synthesis field: Surface functionalization of a nanocarrier and drug encapsulation. Immunogenicity potential and long-term toxicity are the other safety concerns because some nanomaterials may cause the immune response or deposit itself in important organs in the long run. Further, regulatory issues and expensive development discourage clinical adaptation since preclinical and clinical trials are required. These factors are hardly surmountable through strict power or process control but have to be

tackled multidisciplinarily using engineering and sciences of material, pharmacology, and the regulation of TDDS in order to make them practically relatable patient patient-friendly.

6. Future Perspectives

The prospects of Targeted Drug Delivery Systems promise great change as the benefits of nanotechnology, personalized medicine, as well as bioinformatics in the near future. One research direction is the design of efficient smart and multipurpose nanocarriers with combined diagnostic and therapeutic functions and the ability to monitor their work in the body, which is referred to as theranostic systems. They could completely change the face of cancer therapy as well as other diseases associated with damaged tissues and secreted exogenous substances or pathways, such as neurological disorders and chronic inflammation. The last one relates to tailored drug deliveries, where the administering of medications is done in accordance with the patient's genetic makeup as well as the disease indicators. The incorporation of artificial intelligence and machine learning in drug-carrier-based delivery systems can improve the effectiveness of drug delivery, methods of reach, and even dosages to be administered.

Also, advances in an active biodegradable and biocompatible candidate material are likely to lower toxicity and enhance the long-term effects. The factors that make the systems derived from the hybrid carriers involving synthetic and natural polymers include increased stability and targeting efficiency. There is, therefore, a possible enhancement of regulatory standards within clinical translation, government support, and collaboration between researchers, clinicians, and the pharmaceutical industry. Furthermore, due to the growing threat of emerging infectious diseases and their distribution, vaccines and TDDS can be considered an effective solution. Accordingly, TDDS has a great potential to enhance therapy specificity, reducing side effects on the patient's body and thus paving the way to the future of drug delivery and disease control.

Discussion

The study on Targeted Drug Delivery Systems (TDDS) is an ever-surging research area for modifying pharmacotherapy to be more effective, selective, safe and comfortable. This section provides the discussion of findings from the analyzed literature drawing together a synthesis of findings and highlighting the issues that provide a guideline to current as well as future TDDS environment. The nanocarrier-based systems such as Liposomes, Micelles, Dendrimers, and polymeric nanoparticles have shown a fair percentage of increment. Most of these carriers are designed to provide precise release of the drugs at the particular site, thereby enhancing therapeutic impact while minimizing side reactions. Research also confirms that it is more helpful to functionalize nanocarriers with target ligands such as antibodies or peptides because they improve cellular uptake and effectiveness of treatment, particularly in cancer applications. This is preferable to other conventional methods of drug delivery in which drugs are administered systemically and are not targeted [17] [18] [19].

Moreover, the integration of stimuli-responsive mechanisms such as pH, temperature, or redox-sensitive release marks a significant advancement in TDDS. These smart systems are controlled by some internal or external stimuli, which opens the potential of the therapeutic payload when such stimuli are received. This, in turn, minimizes the breakdown of the drug, as well as increases its effectiveness in the area of the body where it is intended to act. The literature mainly discusses the enhanced performance of the pH-sensitive systems in the environment of the tumour. Nevertheless, one must consider the current factors that people will encounter in the process of implementing such theories. Some of the challenges remaining include aggregation of nanoparticles, early release of the drug, low capacity in the loading of the drug, and challenges in manufacturing. There are many a times, the theory of a particular disease and the method of treatment based on Personalized medicine and precision targeting may sound innovative, but in reality, it is far from it because of the biological variation and some constraints of practicality. As for passive targeting strategies, the results indicate that relying on imaginary mechanisms such as the EPR effect to deliver drugs in any instance is not possible for efficient targeting in all cases, and active targeting must be employed to improve their effectiveness [20] [21] [22].

Other factors that tie to the adoption of TDDS in clinical practice include Regulatory, ethical as well and commercial factors. Major challenges facing new technologies in the health care setting include high costs of development, bureaucratic procedures that slow down approval of new technologies, and the absence of a template for evaluating innovative technologies before bringing them to clinical practice. Furthermore, long-term studies of toxicity on newly developed nanomaterials and their delivery systems have been lacking, which is a cause of concern among practitioners and healthcare regulators. These current drawbacks are assumed to be met by emerging trends that include the use of AI in the design of drug carriers, incorporation of theragnostic agents, and revelation of biomimetic carriers. To date, TDDS has also been considered for other diseases apart from oncology, for instance, neurodegenerative diseases, cardiovascular diseases, chronic infections, etc. Overall, it can be noted that, despite the progress being made in the last decade at TDDS, its future and continued success depend on the mutually advantageous collaboration between various disciplines and branches, improvement of the technology, and adequate regulation. Further study and treatments will play a significant role in making the most of it and expanding in use to become a standard approach in treatment in the near future [23] [24] [25] [26].

Conclusion

Targeted Drug Delivery Systems (TDDS) are a revolutionary concept in the modern medicinal field, which provides definite therapeutic effects on the area of interest with minimal side effects. This paper has also found that there is scientific advancement and research work done on TDDS other than the principles, evolution, methodologies and application that have been discussed in this report by reviewing several literature works and totally studying the current practices and innovative ideas. The results validate that TDDS has improved drug selectivity and solubility, especially where it concerns intricate diseases like cancer, neurological disorders, and chronic infections where nanotechnology is applied.

Technological advancement in ligand-mediated targeting and stimuli-responsive release systems, together with multifunctional nanocarriers, holds the place of the significant platform of drugs in biological systems. These advantages of being able to control the release of the drug both spatially and temporally represent a significant advancement over regular drug delivery, as stated above. However, some limitations are; biocompatibility concerns, variation in response, difficulties in mass production and last but not least, regulatory frameworks. These limitations still call for further research, especially with respect to personalized medicine, enhanced biomaterials and effective shipment tracking systems.

Overall, as it has been discussed, TDDS is currently in its early stages, and it still has to face many challenges, but at the same time, it presents many opportunities for the enhancement of healthcare systems globally. With the understanding of enhanced cooperation between various disciplines and further advancements in technologies, TDDS will be seen as one of the key components of the further development of precision medicine. Commitment to moving forward for clinical translation, ethical incorporation, and policy formulation will be crucial to expanding patient care applications all over the world.

References

[1] S. Yasamineh *et al.*, "A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system," *International Journal of Pharmaceutics*, vol. 624, p. 121878, Aug. 2022, doi: https://doi.org/10.1016/j.ijpharm.2022.121878.

[2] D. Ferreira, J. N. Moreira, and L. R. Rodrigues, "New advances in exosome-based targeted drug delivery systems," *Critical Reviews in Oncology/Hematology*, vol. 172, p. 103628, Apr. 2022, doi: https://doi.org/10.1016/j.critrevonc.2022.103628.

[3] V. Murari and S. Shete, "Targeted Drug Delivery Systems: Innovations and Clinical Implications," *International Journal of Pharmaceutical Sciences*, Nov. 2024, doi: https://doi.org/10.5281/zenodo.14043403.

[4] D. D. Deshmane and A. Mundada, "Brain Targeted Drug Delivery System And It's Approaches," *International Journal of Pharmaceutical Sciences*, Mar. 25, 2024. https://www.ijpsjournal.com/article/Brain+Targeted+Drug+Delivery+System+And+Its+Approaches

[5] Simple Pharmanotes, "Introduction to targeted drug delivery systems.," *Simplepharmanotes.com*, Aug. 2021. https://www.simplepharmanotes.com/2022/11/introduction-to-targeted-drug-delivery.html

[6] Fatih Ciftci, A. C. Özarslan, İmran Cagri Kantarci, Aslihan Yelkenci, Ozlem Tavukcuoglu, and Mansour Ghorbanpour, "Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment," *Pharmaceutics*, vol. 17, no. 1, pp. 121–121, Jan. 2025, doi: https://doi.org/10.3390/pharmaceutics17010121.

[7] A. Tewabe, A. Abate, M. Tamrie, A. Seyfu, and E. A. Siraj, "Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives," *Journal of Multidisciplinary Healthcare*, vol. 14, pp. 1711–1724, Jul. 2021, doi: https://doi.org/10.2147/JMDH.S313968.

[8] Imdip.com, "Targeted Drug Delivery System- Characteristics, Advantages, Disadvantages, Types, Applications," *Imdip.com*, Apr. 10, 2023. https://www.imdip.com/2023/04/targeted-drug-delivery-system-characteristics-advantages-types-applications.html

[9] S. M. Matalqah, K. Aiedeh, N. M. Mhaidat, K. H. Alzoubi, Y. Bustanji, and I. Hamad, "Chitosan Nanoparticles as a Novel Drug Delivery System: A Review Article," *Current Drug Targets*, vol. 21, no. 15, pp. 1613–1624, Nov. 2020, doi: https://doi.org/10.2174/1389450121666200711172536.

[10] D. Aggarwal *et al.*, "Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy," *Frontiers in Immunology*, vol. 14, Aug. 2023, doi: https://doi.org/10.3389/fimmu.2023.1203073.

[11] K. Nave, "A polymer pill could soon 'drip feed' drugs into your body for weeks," *WIRED*, Jan. 29, 2017. https://www.wired.com/story/the-delivery-man

[12] M. Fatima, W. H. Almalki, T. Khan, Amirhossein Sahebkar, and Prashant Kesharwani, "Harnessing the Power of Stimuli-Responsive Nanoparticles as an Effective Therapeutic Drug Delivery System," *Advanced Materials*, Mar. 2024, doi: https://doi.org/10.1002/adma.202312939.

[13] A. Alam, R. Karmakar, A. K. Rengan, and M. Khandelwal, "Nanofiber-Based Systems for Stimuli-Responsive and Dual Drug Delivery: Present Scenario and the Way Forward," *ACS Biomaterials Science & Engineering*, vol. 9, no. 6, pp. 3160–3184, May 2023, doi: https://doi.org/10.1021/acsbiomaterials.3c00363.

[14] X. Dai, W. Li, D. Xie, B. Liu, L. Gong, and H. Han, "Stimuli-Responsive Nano Drug Delivery Systems for the Treatment of Neurological Diseases," *Small*, vol. 21, no. 9, Jan. 2025, doi: https://doi.org/10.1002/smll.202410030.

[15] Y. Zhang and B. M. Wu, "Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers," *Gels*, vol. 9, no. 10, pp. 838–838, Oct. 2023, doi: https://doi.org/10.3390/gels9100838.

[16] J. Lee, W. Son, J. Hong, Y. Song, C.-S. Yang, and Y.-H. Kim, "Down-regulation of TNF-α via macrophage-targeted RNAi system for the treatment of acute inflammatory sepsis," *Journal of Controlled Release*, vol. 336, pp. 344–353, Jun. 2021, doi: https://doi.org/10.1016/j.jconrel.2021.06.022.

[17] P. Liu *et al.*, "Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: opportunities and emerging strategies," *Acta Pharmaceutica Sinica B*, Nov. 2020, doi: https://doi.org/10.1016/j.apsb.2020.11.003.

[18] S. Ashique, N. K. Sandhu, V. Chawla, and P. A. Chawla, "Targeted Drug Delivery: Trends and Perspectives," *Current Drug Delivery*, vol. 18, Jun. 2021, doi: https://doi.org/10.2174/1567201818666210609161301.

[19] X. Cong, Z. Zhang, H. Li, Y.-G. Yang, Y. Zhang, and T. Sun, "Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium," *Journal of Nanobiotechnology*, vol. 22, no. 1, Oct. 2024, doi: https://doi.org/10.1186/s12951-024-02892-9.

[20] P. Kesharwani, A. Bisht, A. Alexander, V. Dave, and S. Sharma, "Biomedical applications of hydrogels in drug delivery system: An update," *Journal of Drug Delivery Science and Technology*, vol. 66, p. 102914, Dec. 2021, doi: https://doi.org/10.1016/j.jddst.2021.102914.

[21] A. Shah, S. Aftab, J. Nisar, M. N. Ashiq, and F. J. Iftikhar, "Nanocarriers for targeted drug delivery," *Journal of Drug Delivery Science and Technology*, vol. 62, p. 102426, Apr. 2021, doi: https://doi.org/10.1016/j.jddst.2021.102426.

[22] J. Lou *et al.*, "Advances in Oral Drug Delivery Systems: Challenges and Opportunities," *Pharmaceutics*, vol. 15, no. 2, pp. 484–484, Feb. 2023, doi: https://doi.org/10.3390/pharmaceutics15020484.

[23] H. Tian, F. Zhao, Q. Qi, B. Yue, and B. Zhai, "Targeted drug delivery systems for elemene in cancer therapy: The story thus far," *Biomedicine & Pharmacotherapy*, vol. 166, pp. 115331–115331, Oct. 2023, doi: https://doi.org/10.1016/j.biopha.2023.115331.

[24] A. Sultana, M. Zare, V. Thomas, T. S. S. Kumar, and S. Ramakrishna, "Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects," *Medicine in Drug Discovery*, vol. 15, p. 100134, Sep. 2022, doi: https://doi.org/10.1016/j.medidd.2022.100134.

[25] K. Soumya, N. More, M. Choppadandi, D. A. Aishwarya, G. Singh, and G. Kapusetti, "A comprehensive review on carbon quantum dots as an effective photosensitizer and drug delivery system for cancer treatment," *Biomedical Technology*, vol. 4, pp. 11–20, Dec. 2023, doi: https://doi.org/10.1016/j.bmt.2023.01.005.

[26] M. A. Rahim *et al.*, "Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting," *Cancers*, vol. 13, no. 4, p. 670, Feb. 2021, doi: https://doi.org/10.3390/cancers13040670.